Clinical trials: Solid Malignant Tumor
Advanced Cancer, Advanced Solid Tumor
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Exploratory study to evaluate the effect and safety of the use of Ocoxin® oral solution on the quality of life of paediatric patients with advanced stage solid tumours.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Lymphoma, Hodgkin, Central Nervous System Tumor
- Trial name
- NCT06363201
- Testing
- Ocoxin Oral solution
- Where
- Honduras
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Advanced Solid Tumor Cancer
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for…
- Trial name
- NCT07381829
- Testing
- HC010, Paclitaxel (Chemotherapy), Pemetrexed
- Where
- China
- Volunteers
- 328 people
- Sponsor
- HC Biopharma Inc.
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, Metastatic Solid Tumor
Study of LP-184 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05933265
- Testing
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Lantern Pharma Inc.
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or RP2D of the orally administered PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162.
- Trial name
- NCT01337765
- Testing
- BEZ235 + MEK162
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Refractory Cancer
TCR-engineered T Cells in Solid Tumors: IMA202-101
The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer, Cancer
- Trial name
- ACTengine (NCT03441100)
- Testing
- IMA202 Product, IMADetect®
- Where
- 6 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Immatics US, Inc.
Advanced Solid, Malignant Tumors
Phase I Chinese PK
An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.
- Trial name
- NCT00503711
- Testing
- Vandetanib, Vandetanib 300 mg
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Tumors, Hypoxia
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors.
- Trial name
- NCT00495144
- Testing
- TH-302
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Threshold Pharmaceuticals
Pediatric Solid Tumor, Refractory Tumor
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- Conditions
- Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
- Trial name
- NCT02564198
- Testing
- Ramucirumab
- Where
- 21 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
Solid Tumor, Adult, Acute Myeloid Leukemia
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies (BHARAT-1).
- Conditions
- Solid Tumor, Adult, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma
- Trial name
- BHARAT-1 (NCT05607199)
- Testing
- AUR103
- Where
- 5 sites in India
- Volunteers
- 27 people
- Sponsor
- Aurigene Discovery Technologies Limited
Solid Tumor
A Study in Advanced Solid Tumors
The primary purpose of this study is to help answer the following research question(s): To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with carboplatin [pharmacokinetic…
- Trial name
- NCT01063075
- Testing
- Cetuximab, Carboplatin, 5 - FU
- Where
- 8 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast…
- Trial name
- NCT05112536
- Testing
- Trilaciclib, Cylophosphamide, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- G1 Therapeutics, Inc.
Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL)
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
- Conditions
- Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma
- Trial name
- NCT00647764
- Testing
- SNX-5422 Mesylate Hsp90 inhibitor
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Esanex Inc.
Advanced Solid Tumor
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Phase 1a/1b Trial to evaluate the tolerability and safety of IBI101 monotherapy or in combination with Sintilimab in advanced solid tumor patients.
- Trial name
- NCT03758001
- Testing
- IBI101, Sintilimab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing…
- Trial name
- NCT04475523
- Testing
- CI-8993
- Where
- 6 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- Curis, Inc.
Cancer
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
Present clinical study will be conducted in China to evaluate the pharmacokinetics of single and repeat oral doses of trametinib, the safety profile and the clinical activity in Chinese subjects with solid tumor.
- Trial name
- NCT02939846
- Testing
- Trametinib
- Sponsor
- GlaxoSmithKline
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Solid Tumor
Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology.
- Trial name
- NCT03940820
- Testing
- ROBO1 CAR-NK cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Asclepius Technology Company Group (Suzhou) Co., Ltd.
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.